帕金森病中的病态蛋白标:发展疾病修饰疗法的进展
1Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, NSW, 2050, Australia. nicolas.dzamko@sydney.edu.au.
CNS drugs
|February 17, 2026
概括
针对alpha-synuclein,LRRK2和GCase的新帕金森病 (PD) 疗法在临床试验中显示出前景. 虽然方法各不相同,但在开发PD疾病修饰治疗方面取得了进展.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,目前没有疾病修饰疗法.
- 遗传研究已经确定了PD治疗干预的关键蛋白质标.
- 阿尔法-同核素,LRRK2和GCase都与PD病变和溶酶体功能障碍有关.
研究的目的:
- 审查针对alpha-synuclein,LRRK2和GCase的PD疗法的当前进展情况.
- 突出每个目标所采用的独特治疗策略.
- 通过临床试验管道讨论这些疗法的进步.
主要方法:
- 审查临床试验数据和科学文献.
- 对α-synuclein免疫疗法和小分子方法的分析.
- 对LRRK2的激酶抑制剂和对GCase的伴侣/激活分子的检查.
主要成果:
- 免疫疗法和小分子显示出降低聚合α-synuclein的潜力.
- LRRK2激酶抑制剂正在临床试验的后期阶段.
- 对于与PD相关的GCase突变,GCase激活剂正在进行高级开发.
结论:
- 针对α-synuclein,LRRK2和GCase的疗法代表了PD治疗的有希望的途径.
- 基于特定的蛋白质标,正在开发不同的策略.
- 尽管早期的耐受性,但通过后期临床试验推进这些疗法仍然存在挑战.
相关概念视频
Parkinson's Disease: Overview
2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Lysosomal Hydrolases
4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Alzheimer's Disease: Treatment
1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Neural Regulation
43.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.6K
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K


